Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.

OBJECTIVE Fibroblasts play a major role in the development of systemic sclerosis (SSc), and the occurrence of serum autoantibodies reacting with fibroblast plasma membrane antigens in SSc has been reported. This study was undertaken to investigate whether IgG from SSc sera that react with human fibroblasts modulates the fibroblasts' function. METHODS Sera from 69 patients with SSc (28 with limited cutaneous SSc [lcSSc] and 41 with diffuse cutaneous SSc [dcSSc]), 30 patients with sarcoidosis, and 50 matched healthy controls were examined. We evaluated antibody binding to human skin and lung fibroblasts by cell-based enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence, and flow cytometry. We further investigated the ability of purified IgG to modulate 1) intercellular adhesion molecule 1 (ICAM-1) expression, 2) U937 cell adhesion to fibroblasts, and 3) fibroblast steady-state messenger RNA (mRNA) levels of interleukin-1alpha (IL-1alpha), IL-beta, and IL-6, and IL-6 protein production. RESULTS Of 69 SSc sera tested by cell-based ELISA, 58% bound to normal skin and lung fibroblasts. The prevalence of binding was significantly higher in dcSSc than in lcSSc (P < 0.05). Only IgG from SSc sera that were positive for antifibroblast antibody (AFA) induced a dose-dependent up-regulation of ICAM-1 expression and IL-6 production, enhancement of U937 cell adhesion, and increased levels of IL-1alpha, IL-1beta, and IL-6 mRNA in fibroblasts. Up-regulation of ICAM-1 mediated by AFA IgG was inhibited by the addition of IL-1 receptor antagonist, indicating an autocrine activation loop. CONCLUSION Our findings confirm the presence of AFAs in SSc sera and demonstrate, for the first time, that autoantibodies reacting with fibroblast surface molecules act as an extrinsic stimulus inducing fibroblast activation in vitro.

[1]  C. Chizzolini T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples , 2004, Springer Seminars in Immunopathology.

[2]  U. Haustein,et al.  Lymphocytotoxic autoantibodies in progressive systemic sclerosis , 2004, Archives of Dermatological Research.

[3]  N. Ronda,et al.  Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. , 2002, Arthritis and rheumatism.

[4]  Toshiyuki Yamamoto,et al.  Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.

[5]  T. Yamamoto,et al.  Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. , 2000, Journal of immunology.

[6]  F. Arnett,et al.  Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. , 1999, Arthritis and rheumatism.

[7]  Y. Wu,et al.  Intracellular IL-1 Receptor Antagonist Is Elevated in Human Dermal Fibroblasts That Overexpress Intracellular Precursor IL-1α , 1999, The Journal of Immunology.

[8]  A. Rosen,et al.  Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.

[9]  F. Arnett,et al.  Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. , 1999, Journal of immunology.

[10]  Sato,et al.  Augmented production of chemokines (monocyte chemotactic protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α) and MIP‐1β) in patients with systemic sclerosis: MCP‐1 and MIP‐1α may be involved in the development of pulmonary fibrosis , 1999 .

[11]  C. Ponticelli,et al.  Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-infiammatory phenotype in vitro , 1999, Lupus.

[12]  T. Wright,et al.  Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .

[13]  M. Hasegawa,et al.  Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. , 1999, Clinical and experimental immunology.

[14]  T. Wright,et al.  Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.

[15]  J. Korn,et al.  Biology of the scleroderma fibroblast. , 1998, Current opinion in rheumatology.

[16]  R. Rezzonico,et al.  Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. , 1998, Arthritis and rheumatism.

[17]  Abraham,et al.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers , 1998, Clinical and experimental immunology.

[18]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[19]  T. Krieg,et al.  Pathogenesis of fibrosis: type 1 collagen and the skin , 1998, Journal of Molecular Medicine.

[20]  H. Ihn,et al.  Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. , 1998, The Journal of rheumatology.

[21]  G. Tsay,et al.  Autoantigen components recognizable by scleroderma sera are exported via ectocytosis of fibroblasts. , 1997, British journal of rheumatology.

[22]  M. Khamashta,et al.  Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies , 1997, American journal of reproductive immunology.

[23]  M. Greaves,et al.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.

[24]  Y. Okano,et al.  Antinuclear antibody in systemic sclerosis (scleroderma). , 1996, Rheumatic diseases clinics of North America.

[25]  A. Mantovani,et al.  Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. , 1996, Arthritis and rheumatism.

[26]  C. Savage,et al.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. , 1996, The Journal of clinical investigation.

[27]  P. Boros,et al.  Circulating Fcγ receptor-specific autoantibodies in localized and systemic scleroderma , 1995 .

[28]  P. Boros,et al.  Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma. , 1995, Journal of the American Academy of Dermatology.

[29]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.

[30]  M. De Carlo,et al.  Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. , 1994, The American journal of physiology.

[31]  K. Bost,et al.  Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. , 1992, The Journal of rheumatology.

[32]  O. Hornstein,et al.  Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. , 1992, Journal of the American Academy of Dermatology.

[33]  S. Jimenez,et al.  Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. , 1992, Arthritis and rheumatism.

[34]  J. Korn,et al.  Regulation of ICAM-1 expression and function in human dermal fibroblasts by IL-4. , 1992, Journal of immunology.

[35]  D. Charron,et al.  Induction of interleukin‐1β production in human dermal fibroblasts by interleukin‐1α and tumor necrosis factor‐α. Involvement of protein kinase‐dependent and adenylate cyclase‐dependent regulatory pathways , 1991 .

[36]  J. Johnson,et al.  Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. , 1991, The Journal of investigative dermatology.

[37]  D. Charron,et al.  Induction of interleukin-1 beta production in human dermal fibroblasts by interleukin-1 alpha and tumor necrosis factor-alpha. Involvement of protein kinase-dependent and adenylate cyclase-dependent regulatory pathways. , 1991, Journal of Cellular Biochemistry.

[38]  B. Needleman Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. , 1990, Arthritis and rheumatism.

[39]  M. Sticherling,et al.  IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. , 1990, Journal of immunology.

[40]  M. Moroni,et al.  In vitro modulation of human endothelial cell growth by Kaposi's sarcoma sera. , 1990, Journal of acquired immune deficiency syndromes.

[41]  F. Alderuccio,et al.  Autoantibody to gp50, a glycoprotein shared in common between fibroblasts and lymphocytes, in progressive systemic sclerosis. , 1989, Clinical and experimental immunology.

[42]  J. Seibold,et al.  Anti-IgE autoantibodies in systemic sclerosis (scleroderma). , 1989, Annals of the rheumatic diseases.

[43]  E. Vuorio,et al.  Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. , 1988, The Journal of investigative dermatology.

[44]  T. Krieg,et al.  Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.

[45]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[46]  C. Dinarello,et al.  Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. , 1986, The Journal of clinical investigation.

[47]  S. Lolait,et al.  Autoantibodies to fibroblasts in scleroderma. , 1982, Journal of clinical & laboratory immunology.

[48]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[49]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[50]  N. Rossing Intra- and extravascular distribution of albumin and immunoglobulin in man. , 1978, Lymphology.

[51]  J. R. Reeves,et al.  Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.